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Structure of human cyclin-dependent kinase inhibitor p19INK4d:
comparison to known ankyrin-repeat-containing structures and
implications for the dysfunction of tumor suppressor p16INK4a
Roland Baumgartner1, Carlos Fernandez-Catalan1, Astar Winoto2, 
Robert Huber1, Richard A Engh1* and Tad A Holak1*
Background:  The four members of the INK4 gene family (p16INK4a, p15INK4b,
p18INK4c and p19INK4d) inhibit the closely related cyclin-dependent kinases
CDK4 and CDK6 as part of the regulation of the G1→S transition in the cell-
division cycle. Loss of INK4 gene product function, particularly that of p16INK4a,
is found in 10–60% of human tumors, suggesting that broadly applicable
anticancer therapies might be based on restoration of p16INK4a CDK inhibitory
function. Although much less frequent, defects of p19INK4d have also been
associated with human cancer (osteosarcomas). The protein structures of some
INK4 family members, determined by nuclear magnetic resonance (NMR)
spectroscopy and X-ray techniques, have begun to clarify the functional role of
p16INK4a and the dysfunction introduced by the mutations associated with
human tumors.
Results:  The crystal structure of human p19INK4d has been determined at 1.8 Å
resolution using multiple isomorphous replacement methods. The fold of
p19INK4d produces an oblong molecule comprising five approximately
32-residue ankyrin-like repeats. The architecture of the protein demonstrates
the high structural similarity within the INK4 family. Comparisons to other
ankyrin-repeat-containing proteins (GABPβ, 53BP2 and myotrophin) show
similar structures with comparable hydrogen-bonding patterns and hydrophobic
interactions. Such comparisons highlight the splayed β-loop geometry that is
specific to INK4 inhibitors. This geometry is the result of a modified ankyrin
structure in the second repeat.
Conclusions: Among the INK4 inhibitors, the highest amino acid sequence
conservation is found in the helical stacks; this conservation creates a conserved
β-loop geometry specific to INK4 inhibitors. Therefore, in addition to models
which predict that the conserved helix α6 is responsible for CDK inhibition, a
binding mode whereby the loops of INK4 proteins bind to the CDKs should also
be considered. A similar loop-based interaction is seen in the complex formed
between the ankyrin-repeat-containing protein GABPβ and GABPα. This mode
of binding would be consistent with the observation that p16INK4a is sensitive to
deleterious mutations found throughout this tumor suppressor protein; these
mutations probably destabilize the three-dimensional structure.
Introduction
Prior to cell division, a cell must reproduce a new copy of
each of its chromosomes. This process occurs during a
specific part of interphase, termed the DNA synthesis (or
S) phase. The part of the cell cycle preceding S phase is
referred to as G1. In the eukaryotic cell cycle, passage
through the restriction point and beginning of DNA syn-
thesis (i.e. the G1→S transition) is controlled by cyclins
and cyclin-dependent kinases (CDKs). Cyclin–CDK com-
plexes are activated by the phosphorylation of critical
threonine and tyrosine residues of the CDKs and are
inhibited by specific CDK inhibitors [1,2]. One of these
inhibitors, p19INK4d, belongs to the INK4 family of CDK
inhibitors, which are specific for kinases CDK4 and
CDK6. CDK inhibition by INK4 inhibitors represents one
of several stop mechanisms in the G1→S transition control
point, which ultimately controls progression to DNA
duplication. By inhibiting CDK4 and CDK6, the INK4
proteins can block CDK activity, prevent retinoblastoma
protein phosphorylation and the concomitant activation of
E2F transcription factors [1,2], and thereby induce G1
phase cell-cycle arrest. The INK4 family comprises four
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proteins: p16INK4a, p15INK4b, p18INK4c and p19INK4d [1–3].
The most prominent member of the INK4 protein family
is the multiple tumor suppressor protein p16INK4a [3–5]. It
is believed that p16INK4a dysfunction and the disruption of
the G1→S transition checkpoint may be required for the
genesis of many, or even most, human cancers [1,3]. In
contrast to p16INK4a, other variant INK4 inhibitors are less
frequently associated with cancer: no p18INK4c variant has
been associated with tumorigenesis [6]; one defective
p19INK4d variant is associated with cell lung cancer [7]; and
several p15INK4b variants have been found in different
human cancers [8]. Each member of the INK4 protein
family contains several 32-amino-acid ankyrin-like motifs
that form helix-turn-helix structures [9]. The INK4
inhibitors are highly homologous, for example, human
p19INK4d shares 48% sequence identity with that of human
p16INK4a over a stretch of 130 amino acids [10]. 
Here, we report the crystal structure of human p19INK4d
[10,11] at 1.8 Å resolution. Together with a recently pub-
lished high-resolution X-ray structure of human p18INK4c
[12] and NMR-derived structures of mouse p19INK4d [13]
and p16INK4a [14], the structure of human p19INK4d con-
tributes to our understanding of the correlation between
structure and mutational changes involved in tumorigene-
sis in the INK4 inhibitors. Residues thought to be
involved in the interactions of the INK4 proteins with
CDK4 and CDK6 are also discussed on the basis of the
structures and other biochemical information. Finally, in
order to highlight the distinguishing features of the INK4
fold, we compare the structure of p19INK4d with other
INK4 protein structures and the other recently solved
structures of ankyrin-repeat-containing proteins.
Results and discussion
Tertiary structure
The crystals of p19INK4d contained a single molecule in
the asymmetric unit. Interpretable electron density was
obtained for residues 7–162 of p19INK4d; residues 1–6,
Glu129 and 163–166 were apparently disordered.
p19INK4d forms an approximate ellipsoid with dimensions
55 Å × 25 Å × 20 Å. Figure 1 shows the striking topology
of the highly α-helical p19INK4d with its five almost
equally spaced helix-turn-helix segments between
residues 9–29, 54–62, 77–95, 110–128 and 142–159. With
the exception of the second segment (residues 54–62),
each segment is 16–19 residues long and has a short turn
located between the two helices. All of the β turns in the
helix-turn-helix segments have a central glycine residue
flanked by two residues in β conformations. The crystal
structure confirms a prediction, derived from NMR
studies, of the secondary structure of ankyrin repeats,
which indicated that a typical ankyrin repeat should have
an eight to nine residue long hydrophobic α helix (start-
ing at residue 16) preceded by a glycine-containing
β turn [15].
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Figure 1
Stereoview Cα trace of p19INK4d (red) in a
standard orientation superposed with
p18INK4c (blue). Secondary structure elements
and the N-terminal residue of each inhibitor
(Arg7 and Trp5) are labelled.
The antiparallel helix-turn-helix motifs are connected to
neighboring repeats by long loops perpendicular to the
long axis of the molecule. These loops (or fingers) are
exposed to solvent and point away from the main body of
the molecule. They fold back onto the helical region by
forming type I β turns at segments 39–42, 71–74, 104–107
and 136–139. We designate these loops as ‘β-hairpin-like’;
they are called β sheets by others [12,13]. The helices
from neighboring ankyrin repeats associate via hydropho-
bic interactions, such that each ankyrin pair forms a four-
helix bundle.
Local interactions stabilizing the secondary structure
The highly conserved residues among ankyrin repeats and
among INK4 family members are responsible for either
the stability of the ankyrin fold itself or for the stable
packing between the ankyrin repeats — or for both
(Figure 2). The internal stability of a single helix-turn-
helix segment is gained by the presence of several local
interaction motifs. Ankyrin repeats 2 and 3 clearly reveal a
C-terminal consensus sequence for helix capping in
helices α4 and α6, which corresponds to the so-called
Schellman motif hxpxGh (where h = hydrophobic,
p = polar, G = glycine and x = an arbitrary residue)
[16–18]. Figure 2 shows the high degree of residue conser-
vation at these positions. Hydrogen bonds between back-
bone amide protons and carbonyl oxygen atoms were seen
to link several residues: Ala65(N) to Leu60(O) and
Gly64(N) to Leu61(O) in helix α4; Ala98(N) to Leu93(O)
and Gly97(N) to Leu94(O) in helix α6. These hydrogen-
bonding patterns are characteristic for the C-terminal helix
capping motif [17,18]. In addition, helices α5, α7 and α9
possess an N-terminal proline residue that is known to
facilitate helix formation [18].
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Figure 2
The primary sequence of human p19INK4d
(p19h) and a structural alignment with related
proteins. The aligned sequences are from
p18INK4c, p16INK4a (p15INK4b is not shown
because of its very high identity, 75%, to
p16INK4a), GABPβ, myotrophin and 53BP2.
Residues that are identical in either all four
INK4 family members or all seven proteins
within one ankyrin repeat are marked in bright
yellow; conservation of residue type is marked
in light yellow. The boxed vertical yellow bars
highlight residues that are absolutely
conserved in all ankyrin repeats. Red cylinders
indicate the α helices of p19INK4d (numbering
is as described in the text); the red arrows
indicate β turns. Red underlines indicate α-
helical regions in the other proteins. An
ankyrin consensus sequence is given at the
top of the figure in blue [40].
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Structure
The ankyrin repeat loop structures are stabilized by
hydrogen bonds characteristic of β turns, and by intraloop
hydrogen bonds formed by residues Asn39, Asp71, Asp104
and Asp136 (Figure 3a). These residues are strictly con-
served at equivalent positions among INK4 ankyrin
repeats 1, 2, 3 and 4, respectively (Figure 2), and bridge
peptide amide NH groups in the loop. In general, the
stable stacking arrangement of ankyrin repeats can be
attributed to hydrogen-bond interactions between loops
and hydrophobic interactions within helix bundles. For
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Figure 3
The conserved structural elements in ankyrin-
repeat-containing proteins. (a) Stereoview
illustrating the hydrogen bonds in loops 1 to 4
of p19INK4d, as an example of the hydrogen-
bond network in the β loops of ankyrin-repeat-
containing proteins. Hydrogen bonds shown
in purple are formed by structurally equivalent
residues of p18INK4c, GABPβ and 53BP2;
hydrogen bonds in green are specific to only
one of these proteins. The positions of
hydrogen bonds were calculated using the
program TURBO-FRODO [41]. Carbon
atoms are shown in gray and nitrogen and
oxygen atoms are shown in blue and red,
respectively; sidechains not involved in
hydrogen-bond networks are omitted from the
figure. (b) Stereoview ribbon representation of
p19INK4d showing details of the helix bundle
formed by ankyrin repeats 3 and 4. The figure
shows the hydrophobic core formed by
residues Val94, Val100, Val122, Leu87,
Leu90, Leu126 and Phe125. Sidechains of
hydrophobic residues are shown in gray,
nitrogen and oxygen atoms of basic and
acidic amino acids are given in blue and red,
respectively. Helices are shown in red and
yellow.
the loop stacking (Figure 3a), single mainchain hydrogen
bonds link β turns 2 and 3, and β turns 3 and 4. Further-
more, His79 and His112 bridge the loops by forming pairs
of hydrogen bonds from the histidine ring to the two
flanking loop backbones. His79 is strictly conserved
throughout the INK4 proteins, but His112 is replaced by
aspartate in p16INK4a and p15INK4b.
The helices from neighboring ankyrin repeats pack by
aligning their hydrophobic surfaces. Figure 3b shows an
example of the structural arrangement of amino acids
involved in such hydrophobic interactions. In this
example, a hydrophobic core is formed by residues Val94,
Val100, Val122, Leu90, Phe125 and Leu126. Although
only some of these residues are strictly conserved among
the INK4 proteins (Val122, Leu90 and Leu126), the sub-
stitutions that do occur conserve the amino acid type
(Val94→Leu/His, Val100→Leu, Phe125→Tyr). Figure 3b
also shows the distribution of polar or charged amino acids
that are exposed to solvent.
The second ankyrin repeat has an unusual feature at helix
α3 (formed by residues 45–48 in p19INK4d and residues
41–44 in p18INK4c); in this repeat a short helical loop (α3)
replaces the usual eight-residue helix in the ankyrin
repeat helix-turn-helix motif. This difference is one of
several features that are associated with altered ankyrin
repeat stacking interactions. Another feature is the lack of
hydrogen bonding between the loops from ankyrin
repeats 1 and 2. In addition, two aromatic residues, Phe51
and Phe86, are found at the interface between repeats 2
and 3 such that the bulkier rings distend the helix-bundle
packing compared with the interactions described above
(Figure 3b). This might also contribute to the ‘splayed’
arrangement of β loops 1 and 2.
Comparison to p18INK4c and other INK4 proteins
The INK4 inhibitors p15INK4b, p16INK4a, p18INK4c and
p19INK4d exhibit a high degree of homology (Figure 2),
sharing between 40% and 50% sequence identity (p18 and
p19, 43% identity; p16 and p19, 48% identity over 130
residues; p16 and p18, 45% identity) [8,10,11]. The
sequences of these inhibitors differ most obviously at the
C terminus: p15INK4b lacks the fifth ankyrin repeat, while
p16INK4a lacks both the C-terminal helix and an ankyrin
consensus sequence in the last 22 residues. The first four
ankyrin repeats generally reflect the ankyrin consensus
sequence [9], but each repeat also has specific features
characteristic of INK4 inhibitors (Figure 2). For example,
the first α helix in repeat 1 contains a strictly conserved
Ala-Ala-Ala-Arg-Gly segment, in the second repeat this is
shortened, in the third repeat this segment contains a
strictly conserved His-Asp-Ala-Ala-Arg sequence and in
repeat 4 it is initiated with a Leu-Pro-h-x-Leu-Ala
sequence. The overall similarities in the other segments
are somewhat lower, although helix α6 of the third repeat
contains the conspicuously conserved sequence Gly-Phe-
Leu-Asp-Thr-Leu and the β turns share several individual
conserved residues.
The overall folds of human p16INK4a, p18INK4c and
p19INK4d and mouse p19INK4d, are very similar; however,
a comprehensive detailed comparison must await the
availability of atomic coordinates for the NMR struc-
tures of the INK4 proteins. Figure 1 shows a superposi-
tion of p19INK4d and p18INK4c: the overall backbone root
mean square deviation (rmsd) is 2.0 Å. The folds are
identical, except at the turns of helices α2 and α8 in
ankyrin repeats 1 and 4, respectively (at the back in
Figure 1). These differences correspond to an insertion
in p19INK4d of one residue at position 32, compared to
p18INK4c, and a deletion of two residues after position
129. The deletion results in a relatively sharp turn at the
C-terminal end of helix α8 in p19INK4d (Figure 1). The
structure of p18INK4c was seen to exhibit two unusual
features — a shortened helix α4 and a splayed arrange-
ment of β loops 1 and 2. Both of these features also
occur in the crystal structure of p19INK4d. Otherwise, the
largest deviations are apparent in the β turns and at
helix α9 of the last ankyrin repeat. The unusual feature
of the second ankyrin repeat at helix α3 is found in all
INK4 structures published so far [12–14], and was also
noted in the NMR secondary structure determinations
of p19INK4d and p16INK4a [15,19]. In the p18INK4c struc-
ture, a small cavity is found in this region of the protein
(Figure 4a;  [12]) which, coupled with the high degree of
sequence conservation, led to the proposal that this
could be a general feature of all INK4 proteins [12].
This does not hold for our structure, however, as in
p19INK4d the cavity is filled with two phenylalanine
sidechains (Figure 4).
The structure of the β loops is of particular interest in
terms of INK4 inhibitor functional studies, as the struc-
tures of other ankyrin-repeat-containing proteins have
shown interactions with other proteins to occur via the cor-
responding loops (see discussion below). The geometry of
the splayed β loops 1 and 2, attributed to the shortened
helix α3, seems likely to be a general feature of the
inhibitors due to the conservation of the sequence at helix
α3. Furthermore, although highly flexible loops could be
adapted to their crystalline environment, p19INK4d and the
two p18INK4c monomers in the asymmetric unit are all very
similar despite their diverse crystalline environments.
Loops 1 and 2 are further apart in p19INK4d than in
p18INK4c; this might arise in part from the interposition of
an aromatic sidechain from a symmetry-related molecule.
Each of the two p18INK4c monomers also form crystal con-
tacts via loops 1 and 2. Despite qualitatively different con-
tacts, however, the highly similar loop conformations seen
in the crystal structure provide evidence for the observed
loop arrangement in solution [13,14].
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A high-resolution structure is still lacking for p16INK4a.
Nevertheless, the less precise NMR structures of p16INK4a
(and mouse p19INK4d), together with the higher precision
X-ray structures of p18INK4c and p19INK4d enable many
structural characteristics of p16INK4a to be predicted with
confidence. p16INK4a is folded into a stack of two full and
two half ankyrin repeats [14]. The second repeat shares
the shortened first α helix (α3) of p19INK4d and p18INK4c.
This observation alone strongly indicates the same
unusual splayed geometry of the first and second loops.
Furthermore, the insertion of a proline residue (position
72 in p19INK4d numbering) lengthens the second loop in
p16INK4a. In addition, the p16INK4a NMR structure seems
to indicate that the β turn is absent in loop 1 (Figure 2a of
[14]). Thus, although p16INK4a shares with p18INK4c and
p19INK4d the INK4 characteristic separation of loops 1 and
2, this might be exaggerated in the p16INK4a structure with
possibly a different local fold in loop 1. The p16INK4a helix
stacking is likely to be very similar to that found in
p19INK4d; helices α5 and α6 have the most conserved
amino acid sequences among all INK4 proteins. The
structure, or disorder, of the C-terminal segment of
p16INK4a is less well known. NMR data showed the
segment of residues 134–156 to be disordered [14].
However, truncation experiments removing residues after
position 131 abolished CDK binding. This truncation both
shortens the final helix α8 by one turn and removes the
C-terminal segment. If the abolished binding is not a
result of a disruption of the overall structure but is due to
the missing C terminus, the region might be expected to
adopt structure at least when bound to CDK.
Comparison to known ankyrin-repeat-containing structures
other than INK4 proteins
The structures of three ankyrin-repeat-containing pro-
teins, other than the INK4 proteins, have been elucidated
so far [20–22]. The structure of the 53BP2 ankyrin domain
bound to the p53 core domain and the structure of a
ternary complex of GA-binding protein (GABP, a het-
erodimeric eukaryotic transcriptional regulator comprising
GABPα and GABPβ) bound to DNA were determined by
X-ray crystallography; the structure of myotrophin was
determined by NMR [20]. A detailed comparison of
53BP2 and p18INK4c was carried out by Venkataramani et
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Figure 4
The conformations of Phe51 and Phe86 in
p19INK4d and their relationship to the p18INK4c
structure. (a) Surface representation of
p18INK4c and p19INK4d. Negatively charged
residues are shown in red, positively charged
residues are in blue. Yellow arrows indicate
the cavity present in p18INK4c, but absent in
p19INK4d. (The figure was prepared using the
program GRASP [42].) (b) Stereoview of the
final 1.8 Å 2Fo–Fc electron-density map
contoured at 1σ. The spatial arrangement of
the two aromatic residues, Phe51 and Phe86,
at the interface between ankyrin repeats 2
and 3 is shown.
al. [12], who showed that the overall multirepeat domain
from the 53BP2 protein superimposes well with the
respective regions of the p18INK4c structure. The N-termi-
nal GABPβ subunit of the GABPα–GABPβ heterodimer
consists of three full and two half ankyrin repeats.
Comparison of p19INK4d with the structure of GABPβ also
showed high similarities for these protein folds (Figure 5a).
The pairwise backbone rmsd between p19INK4d and
GABPβ is 5.9 Å. The most significant difference between
the two structures is the position of loop 1. In addition, the
α3 fragment of the second ankyrin repeat unit in the
INK4 proteins consists of just a single turn-helix, whereas
in GABPβ the complete helix-turn-helix is preserved. In
the ankyrin repeat of the GABPβ molecule, the helix adja-
cent to the loop has mostly short residues, whereas the
residues from the helix on the face opposite to the loop are
longer. This asymmetry gives rise to a distinct curvature in
the packing arrangement of adjacent ankyrin-repeat
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Figure 5
Structural comparison of INK4 proteins with
GABPβ and myotrophin. (a) Stereoview Cα
atom superposition of p19INK4d (red) with
GABPβ (blue). (b) Stereoview Cα atom
superposition of p19INK4d (red) with
myotrophin (blue).
helices. p19INK4d and p18INK4c have a similar asymmetric
distribution of long and short residues, although less pro-
nounced than in GABPβ. In the structure of the
GABPβ–GABPα complex, the tips of the loops of GABPβ
form a concave surface that curves around one side of
GABPα. Compared to the p19INK4d structure, the GABPβ
curvature arises primarily from the movement of loop 1
closer towards loop 2 (Figure 5a). It is possible, however,
that this configuration of GABPβ is influenced by binding
to GABPα.
Figure 5b shows a superposition of the p19INK4d structure
with the structure of myotrophin. Myotrophin is a
12.5 kDa protein that appears to have a key role in the ini-
tiation of cardiac hypertrophy. The central part of the
protein contains two full ankyrin-like repeats. The N ter-
minus comprises a well defined ankyrin repeat which, as
in GABPβ and the INK4 proteins, lacks the first N-termi-
nal β-like structure segment. The C terminus of
myotrophin also consists of α-helical elements arranged
roughly into an ankyrin-like fold. A superposition of any of
the two central ankyrin-like repeats of myotrophin with
any of the repeat units of the p19INK4d structure (except
repeat unit 2) shows an rmsd between backbone atoms of
1.4 Å with a total overall rmsd of 10 Å.
It is obvious from inspection of Figure 2, that all of the
proteins used in the sequence alignment possess the
ankyrin consensus sequence. The presence of identical or
conserved residues at specific positions reflects the impor-
tance of these residues in maintaining the characteristic
structural topology of the ankyrin motif. In GABPβ and
53BP2, the hydrogen-bond network between the loop
regions shows the same features as in the INK4 family
proteins (Figure 3a); intraloop hydrogen bonds between
the sidechains of either threonine, aspartate or asparagine
and the loop backbone are present in exactly the same
arrangement. The tips of the loops comprise the consen-
sus sequence (Thr/Asp/Asn)-x-x-Gly which maintains the
hydrogen-bond network while allowing a possibly func-
tional hypervariability at the ‘x-x’ positions.
In p19INK4d, loops 2, 3 and 4 are bridged by His79 and
His112 forming hydrogen bonds to both sides of the
neighbouring loops (Figure 3a). In 53BP2, there are two
histidine residues (His365 and His398) at structurally
similar positions. These histidines are also present in
GABPβ together with a third histidine residue (His34)
bridging loops 1 and 2 in an equivalent way. In addition,
in GABPβ the first loop is integrated into the hydrogen-
bond network and not separated as in INK4 proteins.
Interloop hydrogen bonds can be found between
Leu37(O) and Lys69(N) and from Trp36(O) to the
sidechain of Lys69. The current precision of the NMR
structure of myotrophin does not allow for accurate
hydrogen-bonding comparisons.
The formation of hydrophobic cores between the helices of
two neighboring ankyrin repeats can be found in all the pro-
teins discussed, reflecting the high content of hydrophobic
residues. In the first helix of each ankyrin repeat there is a
conserved alanine residue that probably serves to accommo-
date the larger leucine, isoleucine and valine residues pref-
erentially located in the second helix. This alanine is absent
in the short helix α3 of INK4 proteins but present in
GABPβ, myotrophin and 53BP2, which possess a full seven
to eight residue long helix at this position. Helices are initi-
ated in most cases by typical helix-promoting residues. The
C-terminal helix-capping motif found in repeats 2 and 3 of
p19INK4d is also present in the corresponding regions of
GABPβ, myotrophin and 53BP2.
Binding modes of INK4 proteins to CDK4
The central question regarding the function of INK4
inhibitors concerns the geometry of CDK4/6 binding.
Several studies have aimed to address this question and a
variety of experimental data are available. Possibly the
most important observation is that the four INK4 proteins
appear to be biochemically indistinguishable with respect
to CDK4 versus CDK6 binding [8,10]. Additional impor-
tant data are provided by the structures of other ankyrin-
repeat-containing proteins, the effects of mutations on
binding, and the results of peptide-binding studies. To
date there are two published structures of ankyrin-repeat-
containing proteins in complex with their target proteins:
the 53BP2 ankyrin domain–p53 complex and a complex of
GABPα and GABPβ bound to DNA. The interaction of
the 53BP2 ankyrin domain with p53 is mediated by
residues in the β-loop segments of the ankyrin repeats
[21]. Similarly, GABPβ interacts with GABPα exclusively
through the tips of the four β loops of ankyrin repeats, by
inserting them into a depression in GABPα. As described
in the previous section, the first N-terminal β loop of
GABPβ (loop 1 in p19INK4d) is hydrogen bonded to the
next loop in GABPβ. This differs from the arrangement in
p19INK4d and p18INK4c, where helix α3 of the second
ankyrin repeat unit consists of just a single turn. As a
result, the interactions between α3 and α5, and contacts
between neighboring loops, are less extensive in this
segment of the structure than in the corresponding junc-
tions of other repeat units. By analogy with the inter-
protein interactions found in the 53BP2–p53 and
GABPα–GABPβ complexes, it would be reasonable to
postulate that the INK4 proteins also bind to the CDKs
via their β-loops. It is possible that a plastic deformation
might accompany such CDK binding, which would bring
the loops closer together in the binding site, in an analo-
gous manner to GABPα–GABPβ binding. An ‘inter-
domain’ movement around α3 would facilitate such a
motion. On the other hand, the unusual INK4 β-loop
geometry might be required for CDK4/6 recognition. Evi-
dence against this model includes the screening of small
p16INK4a-derived peptides for binding to CDK4 and
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CDK6, which indicated that the helical region α5–α6 of
the third ankyrin repeat (residues 84–103 of p16INK4a)
comprised the primary CDK4-binding site [23,24]. These
screening experiments tested a series of overlapping 20-
residue peptides that spanned the complete p16INK4a amino
acid sequence. Several appeared to mimic the binding of
INK4 proteins to CDK4: they showed differentiated
binding to CDK4 and CDK6, diverse inhibition of CDK4
and cyclin D1 kinase activity in vitro, and blocked cell-
cycle progression through G1 [23]. Very recently, the same
authors were able to reduce the minimal CDK binding
sequence to ten residues [24]. The ten-amino-acid
minimal CDK4 interacting segment is located between
residues 89–99 in p16INK4a (residues 85–95 in p19INK4d;
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Figure 6
Summary of mutations that affect binding of
p16INK4a to CDK4/6. (a) The amino acid
sequence of p16INK4a is divided into its four
ankyrin repeats (shown boxed in gray).
Mutations that abolish the binding of p16INK4a
to CDK4 are depicted in red letters, and
those that do not significantly affect binding
are in cyan. Green letters indicate mutations
that reduce binding to less than 50%. Circles
mark the surface-exposed residues. The data
presented are based on results from
[14,19,23,25–32]. (b) Stereoview of a
p16INK4a model showing the spatial location of
the mutations listed in (a). Amino acid
mutations that abolish the binding of p16INK4a
to CDK4/6 are shown as red spheres. All
other mutations (no effect or reduced activity)
are indicated by gray spheres. p16h denotes
the human p16INK4a sequence followed by the
residue number.
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that is, it contains a complete ten-residue sequence of
helix α6).
The binding of p16INK4a to CDKs was also studied using
C-terminal deletions of p16INK4a [25]. Eight deletion
series were produced with truncation at residues Asp153,
Glu120, Trp110, Arg80, Glu69, Glu61 and Arg58 of the
wild-type p16INK4a sequence. The only variant that
retained the ability to bind to CDK4 and CDK6 was the
segment truncated at residue 153. All the other trunca-
tions resulted in loss of binding, including the Trp110 and
Glu120 fragments, which each contain three complete
ankyrin repeats in addition to the ten-amino-acid
sequence implicated in the binding to CDK4 and CDK6.
Similar results were obtained by Yang et al. who reported
that deletion to Arg131, or removal of the fourth ankyrin
repeat, abolished CDK binding [26]. At first sight, the
p16INK4a CDK peptide screening and the p16INK4a trunca-
tion data seem to contradict each other. One simple expla-
nation might be that truncations lead to aggregation of
p16INK4a and thus elimination of CDK binding [25,27].
Although the synthetic peptide screening suggests that
the CDK-binding region is located at helix α6, at this
stage, a model that assumes that the binding mode of the
INK4 inhibitors is analogous to those of 53BP2 and
GABPβ proteins cannot be rejected. The answer to this
puzzle can only be provided with the structure of the
binary INK4–CDK complex.
Implications for p16INK4a mutations
Extensive biochemical data are currently available on the
effects of mutations in p16INK4a, especially those muta-
tions that are found in human cancers [1,3,12,24–32]. To
date, three mechanisms that lead to tumor-associated inac-
tivation of p16INK4a have been characterized. These
include point mutation, homozygous deletion and hyper-
methylation of the CpG island spanning the promoter
region of the p16INK4a gene [3,29]. More than 160 mis-
sense mutations have been identified, and it now appears
that deletion and frameshift mutations in p16INK4a are
even more frequent [3,29]. It is now uniformly accepted
that the loss of p16INK4a function (i.e. inhibition of the
cyclin D–CDK4 complex activity or inhibition of entry
into the S phase) is directly connected to the loss of
CDK4/6 binding by the p16INK4a mutants [25,27,29]. We
concentrate here on point mutations that abolish this
binding in vitro, and try to explain them on the basis of
structural considerations. Figure 6 gives an overview of
the distribution of such mutations in the p16INK4a struc-
ture. It includes mutations that are not only identified in
tumors, but those which also reduce notably CDK4-
binding activity in vitro. Considering the model of
β-loop–CDK interactions presented above, the mutation
Tyr44→His is conspicuously exposed to solvent and
distant from helix α6 (Figure 6b). In general, it is evident
that mutations are neither clustered within a specific
region of the protein nor are there any hot spots. The loca-
tions of the mutations, regardless of whether they are
deleterious or not, show no obvious correlation between
solvent-exposed sidechains and those buried inside the
protein. It is clear, however, that most of the mutations
interfere with proper helix packing or preservation of the
hydrogen-bond network, but they may not directly partici-
pate in binding to the CDKs. These mutations lead to
defective folding of the protein and/or increased aggrega-
tion, which ultimately leads to insoluble protein. For
example, Zhang and Peng [27] clearly showed that the
p16INK4a mutants Asp74→Αsn, His87→Pro, His98→Pro,
Val126→Asp, Pro81→Leu, Gly101→Trp and Pro114→Leu
all have disrupted backbone folding with five of the seven
proteins associating to form multimers in solution. An
interesting mutation in this group is Asp74→Asn. This rel-
atively conservative amino acid substitution has a pro-
nounced effect on the structural integrity and stability of
p16INK4a. This is supported by our model structure of
p16INK4a: in the model, substitution of Asp74→Asn
removes the salt bridge between Arg46 and Asp74. Muta-
tions found in familial melanoma provide another illustra-
tion as to how a small disruption of the secondary structure
can have major effects on the function of p16INK4a [25].
For example, based on the p18INK4c structure, it has been
suggested [29] that the Arg87→Pro mutation destabilizes
the entire structure by removing the salt bridge between
Asp84 and Arg87. The corresponding salt bridge is also
present in the structure of p19INK4d (Asp80–Arg83). In
conclusion, it now appears that most tumor-derived muta-
tions in p16INK4a globally destabilize the secondary struc-
ture and sidechain packing of the entire p16INK4a molecule,
rather than locally disrupting the CDK4/6-binding site.
Biological implications 
Cell division is controlled by a series of positive and neg-
ative regulators that act at sequential points throughout
the cell-division cycle. Disturbance of these control
points contributes to cancer by allowing uncontrolled
cell proliferation. During the cell-division cycle, cells in
interphase pass from a stage termed G1 to the DNA
synthesis (or S) phase. At G1, cells irrevocably commit
to DNA synthesis; this point is controlled by protein
complexes consisting of cyclin-dependent kinases
(CDK4 and CDK6) and cyclins D. These complexes are
inhibited by the INK4 family of proteins — p16INK4a,
p15INK4b, p18INK4c and p19INK4d. Genetic alterations
affecting p16INK4a and cyclin D1 are so frequent in
human cancers that inactivation of these proteins is
believed to be necessary for tumor development.
Broadly applicable anticancer therapies might be based
on restoration of p16INK4a CDK inhibitory function.
Although found much less frequently than in p16INK4a,
defects of p19INK4d have also been implicated in human
cancer (osteosarcomas).
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We report here the three-dimensional structure of
human p19INK4d determined by X-ray crystallography.
The fold of p19INK4d produces an oblong molecule built
up from five approximately 32-residue ankyrin-like
repeats. The structure confirms the high structural simi-
larity within the INK4 family members, in particular a
splayed β-loop geometry and modified ankyrin structure
in one repeat. Comparisons to other ankyrin-repeat-con-
taining proteins, including GABPβ, 53BP2 and
myotrophin, show similar structures with specific hydro-
gen-bonding patterns and hydrophobic interactions.
Such comparisons highlight the splayed β-loop geometry
that is specific to INK4 inhibitors. This unusual geome-
try results from the modified ankyrin structure in the
second repeat.
The highest sequence conservation among the INK4
inhibitors is found in the helical stacks, and this gener-
ates the conserved, INK4-specific loop geometry. There-
fore, although models have been predicted in which
helix α6 is responsible for CDK inhibition, a binding
mode whereby the loops of INK4 proteins bind to CDK4
and CDK6 should also be considered. A similar loop-
based interaction is seen in the interaction between the
ankyrin-repeat-containing protein GABPβ and GABPα.
This mode of binding would be consistent with the
observation that p16INK4a is sensitive to deleterious
mutations found throughout the tumor suppressor
protein, rather than to a cluster of mutations near a
single binding region. These mutations are most likely to
lead to the destabilization of the three-dimensional struc-
ture of the INK4 proteins.
Materials and methods
Protein purification and crystallization
The stock solution of human p19INK4d at a concentration of 15 mg/ml
was prepared as described previously [13]. Crystals were grown at
4°C using sitting drops equilibrated against a reservoir of 30% polyeth-
ylene glycol (PEG) 4000, 0.1 M Tris/HCl, 0.2 M MgCl2 (pH 8.5). Drops
(6 µl) were set up at a 1:1 ratio of reservoir to protein solution. Crystals
started to grow from the precipitate as stacks of thin plates after 1.5
months and grew to their maximum size over a period of three weeks.
Single crystals of suitable size, typically 0.1 × 0.1 × 0.2 mm, were
obtained by breaking up stacks and then soaking them in a harvesting
solution containing 35% PEG 4000, 0.1 M Tris/HCl, 0.2 M MgCl2
(pH 8.5). The crystals were monoclinic, with typical cell dimensions of
a = 28.4 Å, b = 54.4 Å, c = 45.6 Å. The crystals were in space group
P21 with one molecule per asymmetric unit. The solvent content was
35% resulting in a Matthews coefficient of 1.95. Heavy-atom deriva-
tives were prepared by conventional soaking experiments (Table 1).
X-ray data collection
The diffraction data were collected in oscillation mode on a 30 cm
image-plate detector (MAR Research, Hamburg, Germany) attached to
a Rigaku RU200 rotating-anode generator providing graphite mono-
chromatized Cu-Kα radiation at 7°C. The oscillation range was 2
degrees resulting in near 100% completeness within 90 frames. The
statistics for native and heavy-atom derivative data are given in Table 1.
Data were indexed, merged and reduced with the DENZO/-
SCALEPACK software package [33]. Very low values for the distortion
matrix were obtained for both monoclinic and orthorhombic lattice
types resulting in possible space groups P2 and P222, respectively.
During refinement and data reduction, the lattice type and space group
clearly proved to be monoclinic P21, with good Rmerge values and spot
rejection below 1%.
Structure determination by multiple isomorphous replacement
Derivative data sets were scaled against the native set using CAD and
SCALEIT of the CCP4 [34] program suite. Heavy-atom positions were
determined with the program RSPS [35] and refined using a vector-
space refinement of the heavy-atom difference Patterson functions
implemented in VECREF [34]. Additionally, these positions could be
visually identified in Harker sections of difference Patterson maps at
different resolutions. All derivatives were analyzed by cross-difference
Fourier maps and referred to the same origin. In the next round, a
maximum-likelihood refinement, as implemented in the program
MLPHARE [34], was used for positional refinement and phase calcula-
tion. The electron density was modified by applying solvent flattening
and histogram matching options in the DM program. The high quality of
the resulting density clearly showed the molecular envelope and sym-
metry-related molecules. Model building was performed from an initial
skeletonization of the electron density using MAIN [36]. Three helices
were identified in the initial skeleton serving as a starting point. With
the exception of six N-terminal residues, four C-terminal residues, and
residue Glu129, the complete polypeptide chain could be traced.
Rigid-body refinement was carried out using X-PLOR [37] confirming
the positional arrangement and unit-cell packing of the model. Several
rounds of interactive model building and refinement with REFMAC [38]
produced a crystallographic R factor and Rfree of 19.6% and 26.4%,
respectively. The resolution of the final model was 1.8 Å. Following the
determination of the p18INK4c structure [12], molecular replacement
using AMORE [39] with standard protocols proved successful using
the p18INK4c coordinates, but failed using the 53BP2 ankyrin-repeat
structure [21]. The refinement statistics are summarized in Table 2.
Research Article  Structure and binding of p19INK4d Baumgartner et al.    1289
Table 1
Data collection statistics.
Data set No. of unique Resolution Phasing power Completeness RCullis Rmerge
† Soaking
reflections (Å) (acentric)* (%) (total) (concentration/ time)
Native 13 017 1.8 — 99.4 — 0.073 —
UO2(CH3CO2)2 5462 2.4 2.96 98.6 0.51 0.085 2.5 mM/ 5 days
Na2WO4 7019 2.2 2.92 99.5 0.52 0.108 5.0 mM/ 3 days
EuCl3 6636 2.2 0.27 94.4 0.98 0.088 2.5 mM/ 23 days
HgCl2 5058 2.4 3.01 85.4 0.79 0.092 5.0 mM/ 3 days
NaAuCl4 6753 2.2 2.98 96.0 0.51 0.082 5.0 mM/ 3 days
*Limiting resolution 3 Å, except for EuCl3 (5 Å). Phasing power = [ΣhklFh2 / Σhkl (FPH,obs – FPH,calc)2]1/2. †Rmerge = ΣhklΣi | Ιhkl,i – <Ιhkl> | / ΣhklΣiIhkl. 
p16INK4a model building 
The p16INK4a backbone conformation was modeled according to that of
p19INK4d using the program O. The model comprises residues
Ser12–Thr137. A two-residue insertion at p16INK4a position 132 (posi-
tion 128 in p19INK4d) was built according to that found in p18INK4c.
There are two residue deletions compared to p19INK4d — after p16INK4a
positions 14 and 35 — and also one insertion — at position 75. These
positions were modeled in the most likely residue conformations as
there are no similar regions in the available coordinate sets. Sidechain
conformations of identical residues were taken from the p19INK4d struc-
ture. The most preferred sidechain conformation was assigned to
mutated residues. Finally, the model was energy minimized using the
program X-PLOR [37].
Accession numbers
The atomic coordinates for the p19INK4d structure have been deposited
with Brookhaven Protein Data Bank (accession code 1BD8).
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Table 2
Data refinement statistics.
No. of protein atoms 1167
No. of water molecules 198
R factor (%)* 19.6
Rfree (%)† 26.4
Root mean square deviation§
bonds (Å) 0.0058
angles (°) 0.96
B factor (Å2) 3.2
Average figure of merit# 0.78
*R factor = Σhkl | Fobs – Fcalc | / ΣhklFobs. †Rfree was calculated using 5%
of the reflections randomly omitted from the refinement. §After final
minimization. #After density modification.
